1244 Stock Overview
A biopharmaceutical company, researches, develops, and commercializes oncology products and other drug candidates for the treatment of patients with various cancers in the Mainland China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
3D Medicines Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$3.33 |
| 52 Week High | HK$8.45 |
| 52 Week Low | HK$1.60 |
| Beta | 1.85 |
| 1 Month Change | 64.85% |
| 3 Month Change | 54.17% |
| 1 Year Change | -54.38% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -89.41% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1244 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -8.5% | -3.9% | -0.5% |
| 1Y | -54.4% | -5.7% | 19.9% |
Return vs Industry: 1244 underperformed the Hong Kong Biotechs industry which returned -5.7% over the past year.
Return vs Market: 1244 underperformed the Hong Kong Market which returned 19.9% over the past year.
Price Volatility
| 1244 volatility | |
|---|---|
| 1244 Average Weekly Movement | 19.4% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in HK Market | 18.6% |
| 10% least volatile stocks in HK Market | 4.1% |
Stable Share Price: 1244's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: 1244's weekly volatility has increased from 13% to 19% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 193 | John Gong | www.3d-medicines.com |
3D Medicines Inc., a biopharmaceutical company, researches, develops, and commercializes oncology products and other drug candidates for the treatment of patients with various cancers in the Mainland China. The company offers Envafolimab, a PD-L1 antibody in the form of subcutaneous injection for the treatment of previously treated microsatellite instability-high (MSI-H)/mismatch repair deficient(dMMR) advanced solid tumors. It is also developing Envafolimab, which is in Phase III clinical trials for advanced BTC and NSCLC; and in Phase II clinical trials G/GEJ and TMB-H advanced cancer, EC, HCC,CRC, NSCLC, microsatellite satble CRC, and dMMR advanced sold tumors.
3D Medicines Inc. Fundamentals Summary
| 1244 fundamental statistics | |
|---|---|
| Market cap | HK$815.99m |
| Earnings (TTM) | -HK$479.28m |
| Revenue (TTM) | HK$520.95m |
1.6x
P/S Ratio-1.7x
P/E RatioIs 1244 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1244 income statement (TTM) | |
|---|---|
| Revenue | CN¥488.82m |
| Cost of Revenue | CN¥81.63m |
| Gross Profit | CN¥407.19m |
| Other Expenses | CN¥856.91m |
| Earnings | -CN¥449.72m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.84 |
| Gross Margin | 83.30% |
| Net Profit Margin | -92.00% |
| Debt/Equity Ratio | 29.7% |
How did 1244 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 06:38 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
3D Medicines Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|